Janssen-Cilag Polska sp. z o.o.

Advertising agencies

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2002-12-17
Share capital
25,050,000.00 PLN
Activity description

Janssen-Cilag Polska is a pharmaceutical company that focuses on innovative medicine, particularly in oncology, immunology, and neuroscience. It has developed and received FDA approval for several treatments, including RYBREVANT FASPRO™ for EGFR-mutated non-small cell lung cancer, CAPLYTA® for major depressive disorder, and DARZALEX FASPRO® for high-risk smoldering multiple myeloma. The company also acquired Halda Therapeutics to enhance cancer treatment options.

Registered address
Iłżecka 24, 02-135 Warszawa, Poland
Website
Social media
Electronic delivery address
AE:PL-98422-76133-RIAIU-27

Financials

Revenue history (in m)

From the notes

Current income tax (CIT due)$5,599,470

Filing timeliness

6 of 6 financial statements were filed late (the longest delay 237 days for 2022). All were audited by a statutory auditor.

  • 202528/09/2026
  • 202416/12/2025
  • 202313/08/2024
  • 202208/03/2024
  • 202126/10/2022
  • 202011/01/2022
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Advertising agencies1 / 3,958
Top <1%
City · Warszawa218 / 56,729
Top <1%
Voivodeship · Mazowieckie268 / 76,892
Top <1%
Country · Poland652 / 297,069
Top <1%

Results vs industry

Revenue
This companyUSD 323.93mMedianUSD 115.83kAverageUSD 1.12m
Net profit
This companyUSD 15.77mMedianUSD 4.00kAverageUSD 75.38k
Operating costs
This companyUSD 303.89mMedianUSD 100.95kAverageUSD 1.02m
Assets
This companyUSD 153.83mMedianUSD 57.45kAverageUSD 671.79k

Offer

Websites

Public procurement

915 tenders recorded as contractor: 175 national ($11,419,793) and 740 EU ($1,313,069,016).

SubjectAmount
Supply of various medicines, including programme medicines
–
Delivery of medicinal products (drug programmes) for Szpital Kolejowy im. dr med. Włodzimierza Roeflera at ul. Warsztatowa 1 in Pruszków.
$213.6K
DFP.271.137.2026.EP Supply of medicinal products
$775.1K

Authorized Representatives

Julie Enevold Brooker age 54 – Management Board Member
Przemysław Brzeski age 53 – Management Board Member
Iwona Gąsiorowska age 50 – Attorney-in-fact (joint)
Joanna Karska age 41 – Attorney-in-fact (joint)
Marcin Soliwodzki age 49 – Attorney-in-fact (joint)

Manner of representation

In the case of a management board consisting of one or two members, the members of the management board represent the company individually before public authorities and third parties, in court and out of court. In the case where the company's management board consists of three or more members, the company is represented by two members of the management board acting jointly, or by a member of the management board acting jointly with an independent commercial proxy or any of the joint commercial proxies.

Ownership

OwnerShare valueStake
Johnson & Johnson International Financial Services Company
$6,766,612.64100%

Beneficial owners

Person

Capital group

The company belongs to the Johnson & Johnson (United States) group, which is its direct owner. The group has 210 companies, 200 of them abroad.

NameCountry
Abiomed Europe GmbHGermany
Abiomed Japan K.K.Japan
Abiomed R&D, Inc.United States
Abiomed, Inc.United States
Acclarent, Inc.United States

Bank accounts

Registered as a VAT taxpayer on 2003-10-31.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 37,728

MSiG notices

Publication dateEvent
Feb 6, 2019Merger plan

Public aid

No public aid cases recorded in the last 10 years.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Astrazeneca Pharma Poland sp. z o.o.
Novartis Poland sp. z o.o.
Bristol-Myers Squibb Polska sp. z o.o.
Takeda Pharma sp. z o.o.
Accord Healthcare Polska sp. z o.o.
Gilead Sciences Poland sp. z o.o.
Amgen sp. z o.o.
Ipsen Poland sp. z o.o.
Medac Gesellschaft Fur Klinische Spezialpraparate M.B.H. Branch (foreign co.)
Servier Polska sp. z o.o.

Change history

DateEvent
2017-01-27PKD change
2015-03-17Switch to PKD 2007
2007-08-21Address change
2003-01-16Share capital increase
2003-01-16Name change

FAQ

Last updated: 2026-11-03